Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

Viking Therapeutics' lead drug candidate VK2735, a dual GLP-1/GIP agonist, shows promise in the competitive weight-loss market with potential for rapid weight loss via injectable form followed by oral maintenance. However, the company faces significant risks including safety concerns from phase 2 trials, long development timelines (phase 3 results not expected until 2027-2028), and likely acquisition by a larger pharmaceutical company if successful.